Jeremy Connors
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeremy Connors has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Demetrios Petropoulos
6 shared publications- Branko Cuglievan
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA
5 shared publications - Miriam B. Garcia
Department of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publications - David McCall
Department of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications - Irtiza N. Sheikh
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
4 shared publications Priti Tewari
4 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
Revumenib in Pediatric Acute Leukemia: Clinical Activity and Differentiation Syndrome from the AUGMENT-101 Study
- 27 October 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
Open AccessRevumenib in Pediatric Acute Leukemia: Clinical Activity and Differentiation Syndrome from the AUGMENT-101 Study
- 10 December 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (2) , 241-244
Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes
- 10 December 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (2) , 241-244
Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes
- 20 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (21) , 2608-2611
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.
- 20 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (21) , 2608-2611
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.
- Open Access
- 22 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1988-1990
Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia
- 22 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1988-1990
Open AccessPost transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia
- Open Access
- 23 August 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (10) , 2073-2084
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of physiologic hematopoiesis, and their expression is regulated by the interaction between KMT2A and menin. Menin inhibitors block this interaction, downregulate the abnormal expression of MEIS1 and other transcription factors and thereby release the differentiation block. Menin inhibitors show significant clinical efficacy against KMT2A-rearranged and NPM1-mutated acute leukemias, with promising potential to address unmet needs in various pediatric leukemia subtypes. In this collaborative initiative, pediatric and adult hematologists/oncologists, and stem cell transplant physicians have united their expertise to explore the potential of menin inhibitors in pediatric leukemia treatment internationally. Our efforts aim to provide a comprehensive clinical overview of menin inhibitors, integrating preclinical evidence and insights from ongoing global clinical trials. Additionally, we propose future international, inclusive, and efficient clinical trial designs, integrating pediatric populations in adult trials, to ensure broad access to this promising therapy for all children and adolescents with menin-dependent leukemias.
- 23 August 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (10) , 2073-2084
Open AccessMenin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of physiologic hematopoiesis, and their expression is regulated by the interaction between KMT2A and menin. Menin inhibitors block this interaction, downregulate the abnormal expression of MEIS1 and other transcription factors and thereby release the differentiation block. Menin inhibitors show significant clinical efficacy against KMT2A-rearranged and NPM1-mutated acute leukemias, with promising potential to address unmet needs in various pediatric leukemia subtypes. In this collaborative initiative, pediatric and adult hematologists/oncologists, and stem cell transplant physicians have united their expertise to explore the potential of menin inhibitors in pediatric leukemia treatment internationally. Our efforts aim to provide a comprehensive clinical overview of menin inhibitors, integrating preclinical evidence and insights from ongoing global clinical trials. Additionally, we propose future international, inclusive, and efficient clinical trial designs, integrating pediatric populations in adult trials, to ensure broad access to this promising therapy for all children and adolescents with menin-dependent leukemias.
- Open Access
- 14 July 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (9) , 1767-1778
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous system. Though more common in older adults, BPDCN has been reported across all age groups, including infants and children. The incidence of pediatric BPDCN is extremely low and little is known about the disease. Pediatric BPDCN is believed to be clinically less aggressive but often with more dissemination at presentation than adult cases. Unlike adults who almost always proceed to a hematopoietic stem cell transplantation in first complete remission if transplant-eligible, the majority of children can be cured with a high-risk acute lymphoblastic leukemia-like regimen. Hematopoietic stem cell transplantation is recommended for children with high-risk disease, the definition of which continues to evolve, or those in relapse and refractory settings where outcomes continue to be dismal. Novel agents used in other hematologic malignancies and CD123 targeted agents, including chimeric antigen receptor T-cells and monoclonal/bispecific antibodies, are being brought into research and practice. Our goal is to provide a comprehensive review of presentation, diagnosis, and treatment by review of pediatric cases reported for the last 20 years, and a review of novel targeted therapies and therapies under investigation for adult and pediatric patients.
- 14 July 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (9) , 1767-1778
Open AccessBlastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous system. Though more common in older adults, BPDCN has been reported across all age groups, including infants and children. The incidence of pediatric BPDCN is extremely low and little is known about the disease. Pediatric BPDCN is believed to be clinically less aggressive but often with more dissemination at presentation than adult cases. Unlike adults who almost always proceed to a hematopoietic stem cell transplantation in first complete remission if transplant-eligible, the majority of children can be cured with a high-risk acute lymphoblastic leukemia-like regimen. Hematopoietic stem cell transplantation is recommended for children with high-risk disease, the definition of which continues to evolve, or those in relapse and refractory settings where outcomes continue to be dismal. Novel agents used in other hematologic malignancies and CD123 targeted agents, including chimeric antigen receptor T-cells and monoclonal/bispecific antibodies, are being brought into research and practice. Our goal is to provide a comprehensive review of presentation, diagnosis, and treatment by review of pediatric cases reported for the last 20 years, and a review of novel targeted therapies and therapies under investigation for adult and pediatric patients.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Medical Education Online
- Vol. 25 (1) , 1777066
Using virtual reality as a replacement for hospital tours during residency interviews
Residency programs invest a significant amount of time and resources on the recruitment process, and maintaining efficiency and cost-effectiveness are very important. Virtual Reality (VR) has becom...
- 1 January 2020
- Published by Taylor & Francis in Medical Education Online
- Vol. 25 (1) , 1777066
Open AccessUsing virtual reality as a replacement for hospital tours during residency interviews
Residency programs invest a significant amount of time and resources on the recruitment process, and maintaining efficiency and cost-effectiveness are very important. Virtual Reality (VR) has becom...